In This Article:
Artera and Tempus are collaborating to expand access to Artera’s AI-based prostate cancer test.
Currently connected to more than 50% of all oncologists practising in the US, Chicago-based Tempus will work with Artera on an exclusive basis to commercialise the latter’s ArteraAI prostate test.
ArteraAI provides predictive and prognostic results for patients with localised prostate cancer. It uses AI to assess prostate needle biopsy images to provide risk stratification and prediction of the benefits of androgen deprivation therapy (ADT) for prostate cancer patients.
The test is the first AI-based risk stratification tool recommended for the evaluation of patients with localised prostate cancer by the NCCN Clinical Practice Guidelines in Oncology.
According to Tempus CEO Dr Ezra Cohen, the management of localised prostate cancer has always been a balance between doing too much and not enough.
“By combining our efforts, we can empower clinicians and patients with critical insights to allow an informed decision at this crucial point in their treatment journey, ensuring that each patient receives the care that is right for them,” said Cohen.
Artera CEO and co-founder Andre Esteva commented: “With Tempus’ unmatched expertise, depth, and broad reach, this collaboration strengthens our shared mission to revolutionise patient care and drive breakthroughs in the field of oncology.”
Prostate cancer is the most common cancer in men in the US. The American Cancer Society’s 2025 estimates 313,780 new cases of prostate cancer in the country a year, with a mortality rate of around 35,770.
In 2021, Paige Prostate became the first AI-based software for prostate cancer risk detection to receive authorisation from the US Food and Drug Administration (FDA).
Last year, Australia-based Telix Pharmaceuticals partnered with Subtle Medical to add the company’s AI-based SubtlePET software to Illuccix, Telix’s imaging agent used in positron emission tomography (PET) scanning for prostate cancer screening.
According to GlobalData’s Intelligence Center, Artera completed a $90m funding round in 2023 and closed $20m last year.
In October 2024, the company received a California laboratory licence from the California Department of Public Health (CDPH), enabling it to offer the ArteraAI test in the state.
"Artera partners with Tempus to expand AI cancer test access" was originally created and published by Medical Device Network, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.